Search

Displaying results 7551 - 7560 of 10000 in total
  1. Drug

    Musa acuminata fruit

    go.drugbank.com/drugs/DB15613
    Approved

    Musa acuminata fruit allergenic extract is used in allergenic testing.

  2. Drug

    YKP-1358

    go.drugbank.com/drugs/DB06109
    Experimental

    YKP1358 is a novel serotonin (5-HT2A) and dopamine (D2) antagonist that has demonstrated potent activity in animals that relates to both positive and negative symptoms of schizophrenia. … In addition, the YKP1358 pharmacological profile suggests a very low potential for extrapyramidal side effects.

    Categories: Dopamine D2 Receptor Antagonists, Serotonin Receptor Antagonists
  3. Drug

    LU-31130

    go.drugbank.com/drugs/DB05828
    Experimental

    It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors. … It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.

  4. Drug

    Rhus Glabra Pollen

    go.drugbank.com/drugs/DB13895
    Approved

    Rhus Glabra Pollen pollen is the pollen of the Rhus Glabra Pollen plant. The pollen is mainly used in allergenic testing.

  5. Drug

    alpha-Conotoxin VC 1.1

    go.drugbank.com/drugs/DB05724
    Experimental

  6. Drug

    ATL-104

    go.drugbank.com/drugs/DB05670
    Investigational

    ATL-104 is a potent mitogen for epithelial cells of the gastrointestinal tract. In animal models, ATL-104 aids regeneration of the gastrointestinal tract after treatment with chemotherapeutic agents.

  7. Drug

    Namilumab

    go.drugbank.com/drugs/DB13037
    Investigational

    Namilumab has been used in trials studying the treatment of Plaque Psoriasis and Rheumatoid Arthritis.

  8. Drug

    Tesaglitazar

    go.drugbank.com/drugs/DB06536
    Investigational

    Tesaglitazar is a dual peroxisome proliferator-activated receptor alpha/gamma agonist which improves apolipoprotein levels in non-diabetic subjects with insulin resistance. … Tesaglitazar is a proposed treatment for type 2 diabetes and has completed several phase III clinical trials, however in May 2006 AstraZeneca announced that they had discontinued further development.

  9. Drug

    AI-128

    go.drugbank.com/drugs/DB05841
    Experimental

    AI-128 is the first human demonstration of sustained release drug administration in the lung. … AI-128 consists of slowly dissolving microspheres designed to control where drug particles go in the lung and how quickly they release their drug.

  10. Drug

    Canis lupus familiaris skin

    go.drugbank.com/drugs/DB10409
    Approved

    Canis lupus familiaris skin allergenic extract is used in allergenic testing.